BB2121 ANTI-BCMA CAR T CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS FROM A MULTICENTER PHASE I STUDY
Author(s): ,
Noopur Raje
Affiliations:
Massachusetts General Hospital Cancer Center,Boston,United States
,
Jesus Berdeja
Affiliations:
Sarah Cannon Research Institute and Tennessee Oncology,Nashville,United States
,
Yi Lin
Affiliations:
Mayo Clinic,Rochester,United States
,
Nikhil Munshi
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
,
David Siegel
Affiliations:
Hackensack University Medical Center,Hackensack,United States
,
Michaela Liedtke
Affiliations:
Stanford University Medical Center,Palo Alto,United States
,
Sundar Jagannath
Affiliations:
Mount Sinai Medical Center,New York,United States
,
Deepu Madduri
Affiliations:
Mount Sinai Medical Center,New York,United States
,
Jacalyn Rosenblatt
Affiliations:
Beth Israel Deaconess Medical Center,Boston,United States
,
Marcela Maus
Affiliations:
Massachusetts General Hospital Cancer Center,Boston,United States
,
Ashley Turka
Affiliations:
Bluebird Bio Inc.,Cambridge,United States
,
Lyh Ping Lam
Affiliations:
Bluebird Bio Inc.,Cambridge,United States
,
Richard A. Morgan
Affiliations:
Bluebird Bio Inc.,Cambridge,United States
,
M. Travis Quigley
Affiliations:
Bluebird Bio Inc.,Cambridge,United States
,
Monica Massaro
Affiliations:
Bluebird Bio Inc.,Cambridge,United States
,
Kristen Hege
Affiliations:
Celgene Corporation,San Francisco,United States
,
Fabio Petrocca
Affiliations:
Bluebird Bio Inc.,Cambridge,United States
James M. Kochenderfer
Affiliations:
Experimental Transplantation and Immunology Branch,National Cancer Institute/Institutes of Health,Bethesda,United States
EHA Learning Center. Berdeja J. Jun 15, 2018; 214444
Jesus Berdeja
Jesus Berdeja

Access to EHA Members only content is an EHA membership benefit. Click here to join EHA or renew your membership here.


Abstract
Discussion Forum (0)
Rate & Comment (0)

Abstract: S138

Type: Oral Presentation

Presentation during EHA23: On Friday, June 15, 2018 from 12:30 - 12:45

Location: Room A8

Background
bb2121 is a second-generation chimeric antigen receptor (CAR) T cell therapy targeting B-cell maturation antigen (BCMA) to redirect T cells to recognize and kill malignant myeloma cells. Initial data from the dose-escalation phase of CRB-401, a first-in-human study of bb2121 in relapsed/refractory multiple myeloma (RRMM), have shown promising efficacy and safety.

Aims
Here, we report updated safety and efficacy results on 43 subjects enrolled in this ongoing study.

Methods
CRB-401 (NCT02658929) is a two-part, phase I study of bb2121 in patients with RRMM. Patients in the dose-escalation had received 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent, or were double refractory, and had ≥ 50% BCMA expression on plasma cells. In the dose-expansion phase, patients had to have received daratumumab and been refractory to their last line of therapy; no BCMA expression was required. Following lymphodepletion with fludarabine (30 mg/m2)/cyclophosphamide (300 mg/m2) given daily for 3 days, patients received 1 infusion of bb2121.

Results
As of 02 Oct 2017, 21 patients had received bb2121 in the 4 dose-escalation cohorts (median follow-up, 35 weeks); no dose-limiting toxicities and no grade 3 neurotoxicities were observed. Cytokine release syndrome (CRS), primarily grade 1-2, was reported in 15 of 21 (71%) patients; 2 patients had grade ≥ 3 CRS that resolved in 24 hours. There were 2 deaths on study; both patients had achieved complete response (CR) and had not progressed. Overall response rate in the 18 evaluable patients in dose-escalation cohorts ≥ 150 × 106 CAR T cells was 94%; 10 of 18 (56%) patients had CR or unconfirmed CR, and 9 of 10 evaluable patients were minimal residual disease (MRD)-negative. With a median follow-up of 40 weeks in the ≥ 150 × 106 dose-escalation cohorts, median response duration and progression-free survival (PFS) had not been reached; PFS rates at 6 and 9 months were 81% and 71%, respectively. Doses of 150 to 300 × 106 CAR T cells were selected for the expansion phase. Results from an additional 5 months of follow-up and initial data from ~20 patients from the expansion cohort will be presented.

 

Conclusion
bb2121 shows promising efficacy at dose levels ≥ 150 × 106 CAR T cells with deep and durable ongoing responses and manageable CRS and neurotoxicities. These data support the potential of bb2121 anti-BCMA CAR T cell therapy as a new treatment paradigm for RRMM.

Session topic: 26. Gene therapy, cellular immunotherapy and vaccination - Clinical

Keyword(s): Cancer immunotherapy, Multiple Myeloma, Phase I, Relapse

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings